Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 5Phase 1/2 3Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 18Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Non-Hodgkin 9Lymphoma, B-Cell, Marginal Zone 4Leukemia 4Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Hodgkin Disease 3Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Nausea 2Leukemia, Lymphocytic, Chronic, B-Cell 2Vomiting 1Orbital lymphoma 1Myelodysplastic Syndromes 1Myasthenia Gravis 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1Central Nervous System Neoplasms 1Burkitt Lymphoma 1

Interventions

spartalizumab 1liposomal doxorubicin 1Salvia hispanica seed extract 1Rituximab 1Prednisone 1Methotrexate 1Gemcitabine 1Dexamethasone 1Clinical Protocols 1Cisplatin 1Cholecalciferol 1Azacitidine 1Asparaginase 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Lymphoma, T-Cell × Rituximab × Clear all
NCT05821192 2023-04-20

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

The First Hospital of Jilin University

Phase NA Unknown
34 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡